INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $4,267,020 | +1193.0% | 78,800 | +1359.3% | 0.09% | +1000.0% |
| Q1 2022 | $330,000 | -55.4% | 5,400 | -72.8% | 0.01% | -60.0% |
| Q3 2021 | $740,000 | -70.9% | 19,851 | -68.1% | 0.02% | -75.3% |
| Q2 2021 | $2,542,000 | +91.7% | 62,270 | +59.4% | 0.08% | +62.0% |
| Q1 2021 | $1,326,000 | +14.1% | 39,070 | +6.9% | 0.05% | +16.3% |
| Q4 2020 | $1,162,000 | -1.7% | 36,542 | -20.6% | 0.04% | -40.3% |
| Q3 2020 | $1,182,000 | +24.3% | 46,047 | -25.6% | 0.07% | -8.9% |
| Q1 2020 | $951,000 | +157.7% | 61,884 | +264.0% | 0.08% | +119.4% |
| Q3 2018 | $369,000 | +55.0% | 17,000 | +50.4% | 0.04% | +28.6% |
| Q1 2018 | $238,000 | +28.0% | 11,300 | -8.2% | 0.03% | -33.3% |
| Q4 2016 | $186,000 | – | 12,303 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |